Technical Analysis for RPRX - Royalty Pharma plc

Grade Last Price % Change Price Change
B 30.05 -0.13% -0.04
RPRX closed down 0.13 percent on Monday, March 18, 2024, on 62 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Inside Day Range Contraction 0.00%
Pocket Pivot Bullish Swing Setup -0.13%
Multiple of Ten Bullish Other -0.13%
NR7 Range Contraction 0.67%
Doji - Bullish? Reversal 0.67%
Multiple of Ten Bearish Other 0.67%
Fell Below 20 DMA Bearish 0.57%
Multiple of Ten Bearish Other 0.57%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
10 DMA Support about 21 hours ago
Fell Below 10 DMA about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products

Is RPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.1552
52 Week Low 25.5437
Average Volume 2,748,206
200-Day Moving Average 28.78
50-Day Moving Average 29.32
20-Day Moving Average 30.34
10-Day Moving Average 29.99
Average True Range 0.65
RSI (14) 52.15
ADX 17.02
+DI 21.64
-DI 17.43
Chandelier Exit (Long, 3 ATRs) 29.70
Chandelier Exit (Short, 3 ATRs) 31.17
Upper Bollinger Bands 31.44
Lower Bollinger Band 29.25
Percent B (%b) 0.37
BandWidth 7.23
MACD Line 0.17
MACD Signal Line 0.27
MACD Histogram -0.0974
Fundamentals Value
Market Cap 13.42 Billion
Num Shares 447 Million
EPS 0.39
Price-to-Earnings (P/E) Ratio 77.05
Price-to-Sales 7.40
Price-to-Book 2.13
PEG Ratio 0.09
Dividend 0.79
Dividend Yield 2.63%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.56
Resistance 3 (R3) 30.55 30.38 30.47
Resistance 2 (R2) 30.38 30.25 30.38 30.45
Resistance 1 (R1) 30.21 30.17 30.12 30.22 30.42
Pivot Point 30.04 30.04 29.99 30.04 30.04
Support 1 (S1) 29.87 29.91 29.79 29.88 29.68
Support 2 (S2) 29.70 29.83 29.70 29.65
Support 3 (S3) 29.53 29.70 29.63
Support 4 (S4) 29.54